Martinez-Gomez Carlos, Michelas Marie, Scarlata Clara-Maria, Salvioni Anna, Gomez-Roca Carlos, Sarradin Victor, Lauzéral-Vizcaino Françoise, Féliu Virginie, Dupret-Bories Agnès, Ferron Gwénaël, Sarini Jérôme, Devaud Christel, Delord Jean-Pierre, Balança Camille-Charlotte, Martinez Alejandra, Ayyoub Maha
Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France.
Department of Surgery, IUCT-Oncopole, 31059 Toulouse, France.
Cancers (Basel). 2022 Jul 28;14(15):3679. doi: 10.3390/cancers14153679.
Tumor-infiltrating exhausted PD-1CD39 tumor-antigen (Ag)-specific CD4 T cells contribute to the response to immune checkpoint blockade (ICB), but their circulating counterparts, which could represent accessible biomarkers, have not been assessed. Here, we analyzed circulating PD-1CD39 CD4 T cells and show that this population was present at higher proportions in cancer patients than in healthy individuals and was enriched in activated HLA-DR and ICOS and proliferating KI67 cells, indicative of their involvement in ongoing immune responses. Among memory CD4 T cells, this population contained the lowest proportions of cells producing effector cytokines, suggesting they were exhausted. In patients with HPV-induced malignancies, the PD-1CD39 population contained high proportions of HPV Ag-specific T cells. In patients treated by ICB for HPV-induced tumors, the proportion of circulating PD-1CD39 CD4 T cells was predictive of the clinical response. Our results identify CD39 expression as a surrogate marker of circulating helper tumor-Ag-specific CD4 T cells.
肿瘤浸润性耗竭的PD-1⁺CD39⁺肿瘤抗原(Ag)特异性CD4⁺ T细胞有助于对免疫检查点阻断(ICB)的反应,但其循环中的对应细胞,可能代表可获取的生物标志物,尚未得到评估。在此,我们分析了循环中的PD-1⁺CD39⁺ CD4⁺ T细胞,并表明该群体在癌症患者中的比例高于健康个体,且在活化的HLA-DR和ICOS以及增殖的KI67⁺细胞中富集,表明它们参与了正在进行的免疫反应。在记忆CD4⁺ T细胞中,该群体产生效应细胞因子的细胞比例最低,表明它们已耗竭。在HPV诱导的恶性肿瘤患者中,PD-1⁺CD39⁺群体包含高比例的HPV Ag特异性T细胞。在接受ICB治疗的HPV诱导肿瘤患者中,循环中的PD-1⁺CD39⁺ CD4⁺ T细胞比例可预测临床反应。我们的结果确定CD39表达为循环中辅助性肿瘤Ag特异性CD4⁺ T细胞的替代标志物。